News

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

  • Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.
    03/13/2025

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

  • Raanana, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the "SEC").
    03/11/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

The price of Polyrizon Ltd. (PLRZ) is 0.61 and it was updated on 2025-03-17 11:00:32.

Currently Polyrizon Ltd. (PLRZ) is in undervalued.

News
    
News

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

  • Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.
    Mon, Mar. 10, 2025

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

  • Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company's advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company's recently announced U.S. patent application which encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery.
    Thu, Jan. 30, 2025

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

  • Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
    Thu, Jan. 23, 2025

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

  • Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of a national phase patent application by the United States Patent and Trademark Office (“USPTO”). The patent application encompasses key aspects of Polyrizon's two core platform technologies: Capture and Contain (C&C™), a nasal blocker technology, and Trap and Target (T&T™), designed for advanced nasal drug delivery. Both technologies represent Polyrizon's commitment to creating innovative solutions for protecting and treating via the nasal cavity.
    Mon, Dec. 30, 2024

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

  • Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product development.
    Thu, Dec. 19, 2024
Press Releases
StockPrice Release

Polyrizon signs non– binding loi to expand its innovative intranasal drug delivery platform for psychedelic-based treatments

  • 03/14/2025

Polyrizon launches preclinical studies for intranasal naloxone to combat opioid overdose using cutting-edge platform

  • 03/13/2025

Polyrizon ltd. files annual report on form 20-f for the fiscal year ended december 31, 2024

  • 03/11/2025

Polyrizon initiates preclinical studies for intranasal naloxone targeting opioid overdose based on its innovative t&t platform

  • 03/10/2025

Polyrizon announces filing of divisional patent application for its innovative trap & target™ (t&t) intranasal drug delivery platform

  • 01/30/2025

Polyrizon commences gmp manufacturing preliminary process for its pl-14 allergy blocker in preparation for planned 2025 clinical trial

  • 01/23/2025

Polyrizon announces publication of u.s. national patent application for its innovative hydrogel nasal technologies

  • 12/30/2024

Polyrizon appoints dr. michal meir as senior director of regulatory and clinical affairs

  • 12/19/2024

Polyrizon's moving forward with expected 2025 clinical trial - entered manufacturing agreement for its pl-14 allergy blocker

  • 12/18/2024

Polyrizon announces appointment of vp of regulatory affairs and quality assurance

  • 12/13/2024

Polyrizon enters into gmp manufacturing agreement for ctm supply of its pl-14 allergy blocker in preparation for planned 2025 clinical trial

  • 12/02/2024

Aegis capital corp. acted as sole bookrunner on a $4.2 million (ipo) initial public offering for polyrizon ltd. (nasdaq: plrz)

  • 10/30/2024

Polyrizon announces closing of $4.2 million initial public offering

  • 10/30/2024

Polyrizon announces pricing of $4.2 million initial public offering and listing on the nasdaq capital market under new ticker “plrz”

  • 10/28/2024
More Headlines
News

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

  • The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
  • 12/18/2024

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

  • Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions.
  • 12/13/2024

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

  • The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
  • 12/02/2024

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

  • NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).
  • 10/30/2024

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

  • Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the closing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds were $4.2 million, prior to deducting underwriting discounts and offering expenses.
  • 10/30/2024

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

  • Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the pricing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds are expected to be $4.2 million, prior to deducting underwriting discounts and offering expenses.
  • 10/28/2024
Unlock
PLRZ Ratings Summary
PLRZ Quant Ranking